MAPT and Alzheimer disease: Although most clinical trials primarily targeting Aβ and tau have not been successful (Avgerinos et al., 2021., Liu and Wang, 2019; Lu et al., 2020), a recent study indicates clinical benefit in participants with early AD under treatment with an antibody binding soluble amyloid-beta protofibrils (Lecanemab) (van Dyck et al., 2022).